the old formula will still be available in 2019, against a backdrop of controversy

<p clbad = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "While the drug agency announced that the drug would still be available a year, controversy over the change of formulation and cases of adverse effects continues. "data-reactid =" 22 ">While the drug agency announced that the drug would still be available a year, controversy over the change of formulation and cases of adverse effects continues.

The old formula of Levothyrox (Euthyrox) will continue to be offered to patients with hypothyroidism throughout the year 2019, according to a statement from the National Agency for Drug Safety (ANSM) published October 31. "The ANSM has asked Merck laboratory to continue its availability in France in 2019 to allow patients still treated with Euthyrox to adapt to a new treatment," says the statement, which states that the drug does not will be available only for a limited time and in limited quantities.

"We will import the same number of boxes as in 2018, that is 50,000 per month," says Valérie Leto, pharmacist in charge of the Merck laboratory. In total, between 3 and 4 million boxes of levothyroxine-based specialties are sold every month, regardless of brand name. "We have been importing Euthyrox from Germany since October 2017, at the request of the French health authorities," says Valérie Leto.

<p clbad = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "READ ALSO – What are the symptoms of hypothyroidism? "data-reactid =" 25 ">READ ALSO – What are the symptoms of hypothyroidism?

<p clbad = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "The end of the programmed Levothyrox"data-reactid =" 26 ">The end of the programmed Levothyrox

The announcement was welcomed Tuesday by the badociation "Living without thyroid", which evokes a "breath of fresh air for patients who do not support the new formula." As a reminder, the active ingredient (the hormone levothyroxine) remains the same, only the excipients differ. But the measure is still considered insufficient: "It postpones the problem. What would be needed is the durability of the two formulas side by side, "said Beate Bartès, the president of" Living without thyroid ".

<p clbad = "canvas-atom-canvas-text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Yet, the end of the old formula of Levothyrox is already scheduled, and the change has already been made in Switzerland in April 2018 and other European countries are preparing to follow suit. "21 European countries (…) Read more on Figaro.fr

"data-reactid =" 28 "> However, the end of the old Levothyrox formula has already been programmed and the change has already been made in Switzerland in April 2018 and other European countries are preparing for it follow suit: "21 European countries (…) Read more on Figaro.fr

<p clbad = "canvas-atom-text-canvas Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = "Levothyrox: new controversy over the composition of the drug
Levothyrox: the new formula will arrive in 21 European countries in 2019
The Agence du médicament confirms the good quality of the new Levothyrox
Hypothyroidism: Some people could be misdiagnosed
Sign up for the Le Figaro Santé newsletter
"data-reactid =" 29 "> Levothyrox: new controversy over the composition of the drug
Levothyrox: the new formula will arrive in 21 European countries in 2019
The Agence du médicament confirms the good quality of the new Levothyrox
Hypothyroidism: Some people could be misdiagnosed
Sign up for the Le Figaro Santé newsletter